PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1

PD-L1 expression

Associations